title: Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.
abstract: Hepatitis B virus (HBV) is a very complex and intricate DNA structure associated with a particular genomic organization and replication cycle. However, many years of investigations allowed clarification of the real HBV natural history, through a deeper knowledge of the behavior of HBV antigens and viral structures. Several of the old diagnostic tools, such as HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) determinations, gained prominence now, since the variation of both HBsAg and HBeAg plasma levels was shown to predict treatment response. In addition, the availability of more sensitive methods, such as HBV DNA detection by real-time PCR, has improved the current knowledge of the relationships between HBV replication levels and the natural history of the disease. It is now well established that some HBV genotypes are associated with a better response to treatment with pegylated interferon. Despite the widely accepted value of liver biopsy as a staging tool, transient elastography is being increasingly acknowledged as a non-invasive method to assess liver stiffness, chiefly for detection of advanced fibrosis. Current international guidelines for the management of chronic hepatitis B have provided several accurate biochemical and serological criteria for selecting patients for treatment, allowing a higher number of cases to be enrolled into antiviral therapy. This review describes the different serological markers used for the study of HBV and their clinical significance. It also deals with methods used for detection of genotypes and HBV DNA, emphasizing the effectiveness of such determinations for both patient selection and chronic hepatitis B therapy/monitoring.
authors.affiliation: Gastroenterology and Hepatology Department, School of Medicine, University of Rosario, Rosario, Santa Fe, Argentina.
authors.forename: Fernando
authors.initials: F
authors.lastname: Bessone
mesh_terms: D000956:Antigens, Viral / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D019468:Disease Management; D054459:Elasticity Imaging Techniques / Q000379:methods*; D005838:Genotype; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D011092:Polyethylene Glycols / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D000095022:Interferon Lambda
chemical_list: D000956:Antigens, Viral; D015415:Biomarkers; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a
keywords: Anti-HBsAg; Chronic hepatitis B; HBV; HBV DNA; HBV genotypes; HBeAg; HBsAg; Hepatitis B